A mutated Wickerhamomyces ciferrii strain over-producing tetraacetylphytosphingosine and process for preparing tetraacetylphytosphingosine using the same
The construction of an expression plasmid with a CEN/ARS replication origin and uracil selection marker in Wickerhamomyces ciferrii enhances TAPS production, addressing inefficiencies in conventional methods and achieving high titers.
Patent Information
- Application Number
- KR1020220110854
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2022-09-01
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-09-01
AI Technical Summary
Conventional methods for enhancing tetraacetylphytosphingosine (TAPS) production in Wickerhamomyces ciferrii strains face challenges such as high time and labor requirements and the presence of selection markers, necessitating the development of efficient genetic tools for overexpression.
An expression plasmid with a CEN/ARS replication origin and uracil selection marker is constructed for Wickerhamomyces ciferrii, incorporating genes for serine palmitoyl-transferase and sphinganine C4-hydroxylase, and the LCB4 gene is deleted to enhance TAPS production.
The method significantly increases TAPS production capacity, achieving titers up to 20 g/L, with the engineered strain showing improved metabolic flow and productivity.
Smart Images

Figure 112022092209358-PAT00015_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a mutant strain of Wicker hemomyces siferae with enhanced TAPS production capacity and a method for producing TAPS using the same. Background Technology
[0003] Biorefinery is a technology that produces high-value-added products, such as biochemicals, biopolymers, and biofuels, using biomass as a raw material. Biomass, an alternative to fossil fuels, consists of renewable organic materials including plants, animals, and microorganisms; unlike limited fossil fuels, solar energy is an infinite resource as long as it exists. Therefore, it can serve as an alternative to reduce dependence on petroleum and solve the problem of greenhouse gases. In recent years, the use of various platforms, such as yeast, E. coli, Bacillus subtilis, and filamentous fungi, has increased. Among these, yeast was the first eukaryotic organism to undergo genome sequencing and possesses extensive technological platforms in systems biology and synthetic biology.
[0004] Meanwhile, ceramide is known as the most important skin lipid, accounting for 40–50% of lipids, and is the main component of the lipid layer in the structure of the stratum corneum (SC), the uppermost layer of the human skin epidermis; it is used in cosmetics such as moisturizers and hand creams. Ceramide is a sphingolipid in which acyl chains of fatty acids are connected to sphingoid bases via amide bonds, and these sphingoid bases have sphingosine, phytosphingosine, and sphinganine as their backbones. Sphingolipids are components that form the membrane structures of all living organisms and play a key role in cell growth and proliferation. Tetraacetyl phytosphingosine (TAPS) is a fully acetylated form of phytosphingosine; in particular, TAPS is reported to be important for ceramide synthesis because it can be converted into phytosphingosine, one of the sphingoid bases of ceramide, through a process of removing the acetyl group. TAPS is synthesized from the condensation of L-serine and palmitoyl-CoA through the catalytic action of serine palmitoyltransferase (SPT). This synthesizes 3-keto-sphinganine, which is converted into sphinganine and phytosphingosine (see Fig. 1). Phytosphingosine has a D-erythro(2S, 3R) structure identical to that of sphingosine found in human skin. Furthermore, it is reported to be effective for skin diseases accompanied by chronic inflammation, such as atopic dermatitis, by penetrating deep into the skin and promoting ceramide synthesis.
[0005] Ciferi, known as Pichia ciferrii, which has the characteristic of producing and secreting TAPS outside the cell, is a non-traditional yeast with characteristics different from traditional Saccharomyces cerevisiae yeast. Many studies have been conducted to improve TAPS production in W. ciferrii, typically through methods such as constructing strains with improved TAPS production via random mutation using ethyl methanesulfonate (EMS), γ-ray irradiation, UV, and NTG, or through genetic modification.
[0006] Among them, conventional methods for manipulating Wicker hemomyces cyperae are genetic manipulation methods based on homologous recombination, specifically involving the replacement of promoters or gene insertion to overexpress specific genes. However, there were several disadvantages, such as the high time and labor required to remove selection markers and the presence of traces in the genes. Therefore, it is still necessary to establish efficient genetic tools for overexpression. The problem to be solved
[0008] One objective of the present invention is a novel Wicker hemomyces cyperai ( Wickerhamomyces ciferrii ) It is to provide an expression plasmid for genetic manipulation.
[0009] Another objective of the present invention is to have a Wicker hemomyces cyperai with enhanced tetraacetylphytosphingosine production capacity ( Wickerhamomyces ciferrii It is to provide a variant strain.
[0010] Another objective of the present invention is to provide a composition for producing tetraacetylphytosphingosine comprising the above mutant strain.
[0011] Another objective of the present invention is to provide a method for producing tetraacetylphytosphingosine using the above-mentioned Wicker Hemomyces cyperai mutant strain.
[0012] Another objective of the present invention is to provide a method for producing the above-mentioned Wicker Hemomyces cyperai variant. means of solving the problem
[0014] Each description and embodiment disclosed herein may be applied to each other description and embodiment. That is, all combinations of the various elements disclosed herein fall within the scope of the invention. Furthermore, the scope of the invention is not to be limited by the specific descriptions provided below.
[0015] Furthermore, a person skilled in the art can recognize or identify a number of equivalents to the specific embodiments of the invention described in this application using only ordinary experiments. Furthermore, such equivalents are intended to be included in the invention.
[0016] Furthermore, throughout the entire specification of this application, when a part is described as "including" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.
[0018] The present invention is based on the novel discovery that, in order to solve the problem of difficulty in applying expression plasmids to conventional Wicker Haemomysis ciferae strains, an expression plasmid for transforming Wicker Haemomysis ciferae is constructed, and that TAPS production can be more effectively enhanced during genetic manipulation using this.
[0019] Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the attached drawings.
[0021] To achieve the above objective, the present invention (wicker hemomysis cyperai) Wickerhamomyces ciferrii Provides an expression plasmid for transformation in a ) strain.
[0022] Specifically, the expression plasmid is characterized by including a CEN / ARS replication origin and a uracil selection marker.
[0023] The term of the present invention, “Wicker hemomysis cyperai ( Wickerhamomyces ciferriiThe term “) strain” refers to a yeast strain that produces various sphingolipids, including TAPS. It is known that TAPS is biosynthesized from serine and palmitoyl-CoA via a chain reaction in the aforementioned strain. More specifically, first, 3-ketosphingonine is synthesized through the condensation reaction of serine and palmitoyl-CoA by serine C-palmitoyltransferase, which is expressed by the LCB1 and LCB2 genes. Second, 3-ketosphingonine is reduced to 3-ketosphinganine by 3-ketosphinganine reductase, which is expressed by the TSC10 gene, and third, 3-ketosphinganine is converted into sphinganine, which is expressed by the SYR2 gene. It is converted to phytosphingosine by the addition of a hydroxyl group by C-4-hydroxylase (Sphinganine C-4-hydroxylase). Finally, TAPS is produced by acetyltransferases expressed by the Slli1 and Atf2 genes, in which acetyl groups are attached to the N and O portions of phytosphingosine (Fig. 1).
[0025] In this invention, the term “plasmid” refers to a representative episomal DNA molecule physically separated from chromosomal DNA essential for growth. It was first coined in 1952 by American geneticist J. Lederberg to mean a DNA molecule capable of independently replicating outside of bacterial chromosomes. Plasmids exist in various sizes ranging from 1 kilobase to 1 megabase; while most are circular, linear plasmids have also been reported. Plasmids can be isolated from bacteria and transferred into new host cells, and these easily transformable plasmids are widely used in genetic engineering. They are used to extract DNA from bacteria and facilitate the replication of recombinant DNA sequences using vectors containing multiple restriction enzyme cloning sites. Additionally, expression vectors are used to express desired genes as proteins within cells.
[0026] In this invention, the term “replication origin” refers to a specific DNA sequence on the genome where DNA replication begins, also known as the replication initiation point. In the case of prokaryotes, DNA replication begins from a single replication origin and proceeds bidirectionally. It is characterized by the repeated appearance of A and T nucleotides, and due to the high content of A and T, the double helix structure is more easily unwound than in other regions of the DNA.
[0027] In the present invention, the replication origin is characterized as being a CEN / ARS replication origin.
[0028] In the above CEN / ARS, CEN stands for centromere and ARS stands for autonomous replicating sequence, which is a region that characterizes the type of yeast gene carrier.
[0029] In the present invention, the term “selection marker” refers to a marker used to confirm whether a plasmid has been successfully injected into a transformant, and is also referred to as a selection marker or a selection marker. The present invention is characterized by the use of a uracil selection marker to confirm whether the expression plasmid has been successfully introduced into the Wicker Haemomyces siferae strain via transformation.
[0030] The above uracil is a derivative of a pyrimidine base that exists in RNA but not in DNA. In the present invention, uracil selection markers may be, for example, 5-FOA ((5-Fluoroorotic acid), Monohydrate), but are not limited thereto.
[0031] The above 5-Fluoroorotic acid (5-FOA) is used in yeast genetics to confirm the absence of the URA3 gene, because URA3 leads to death through the decarboxylation reaction of 5-FOA into the toxic metabolite 5-fluorouracil.
[0032] In a specific embodiment of the present invention, a uracil-requiring strain was produced using 5-FOA during the strain screening process. In addition, it was confirmed that the uracil-requiring strain produced in this way contains 5-FOA as a uracil selection marker within the plasmid.
[0034] The expression plasmid of the present invention may have additionally inserted a gene encoding serine palmitoyl-transferase and a gene encoding sphinganine C4-hydroxylase.
[0035] In the present invention, the term “Serine palmitoyl-transferase” is a protein involved in the production of 3-ketosphinganine from L-serine and palmitoyl-CoA.
[0036] The above protein may be an amino acid sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or more homology or identity with SEQ ID NO. 1. Furthermore, it is obvious that an auxiliary protein having an amino acid sequence in which some sequences are deleted, modified, substituted, or added is included within the scope of this application, provided that such an amino acid sequence has such homology or identity and exhibits efficacy corresponding to the above protein.
[0037] In addition, polypeptides having serine palmitoyl-transferase activity may also be included without limitation as probes that can be prepared from known gene sequences, for example, polypeptides encoded by polynucleotides that are hybridized under strict conditions with a sequence complementary to all or part of the base sequence encoding said polypeptide.
[0038] The above serine palmitoyl-transferase protein may be encoded by LCB1, LCB2 polynucleotides, or a combination thereof.
[0040] In the present invention, the term "polynucleotide" has a meaning that comprehensively includes DNA or RNA molecules, and the nucleotide, which is the basic constituent unit of the polynucleotide, may include not only natural nucleotides but also analogs in which the sugar or base site is modified (see Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews, 90:543-584 (1990)).
[0041] The polynucleotide encoding a protein containing the amino acid sequence of SEQ ID NO. 1 may be included without limitation as long as it is a sequence capable of encoding a serine palmitoyl-transferase protein or a protein having the activity of a functional fragment thereof.
[0042] For example, the LCB1 gene may contain the polynucleotide of SEQ ID NO. 2, and the LCB2 may contain the polynucleotide of SEQ ID NO. 3.
[0043] Furthermore, it is evident that the present invention may also include a sequence in which the gene sequence is codon-optimized based on the codon appearance frequency of the parent strain.
[0045] In the present invention, the term “sphinganine C4-hydroxylase” refers to a protein involved in the conversion of sphinganine to phytosphingosine.
[0046] The above protein may be an amino acid sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or more homology or identity with SEQ ID NO. 4. Furthermore, it is obvious that an auxiliary protein having an amino acid sequence in which some sequences are deleted, modified, substituted, or added is included within the scope of this application, provided that such an amino acid sequence has such homology or identity and exhibits efficacy corresponding to the above protein.
[0047] The above sphinganine C4-hydroxylase may be encoded by SYR2. The above SYR2 gene may include, for example, the polynucleotide of SEQ ID NO. 5.
[0049] The expression plasmid of the present invention may additionally include a homology arm of a gene encoding a long-chain base kinase.
[0050] In the present invention, the term “long-chain base kinase” refers to a protein that converts sphinganine to sphinganine-1-P and may include the amino acid sequence of SEQ ID NO. 6.
[0051] The above protein may be encoded by an LCB4 polynucleotide sequence, and as an example, the above gene LCB4 sequence may include the polynucleotide of SEQ ID NO. 7.
[0052] In the present invention, the term "homology arm" refers to the preservation of a certain trait during the process of evolution, and this may apply to morphological traits, molecular traits, or gene sequences. Therefore, a homology arm can be said to be a homologous nucleotide sequence.
[0053] In one embodiment, the expression plasmid of the present invention may be an expression plasmid having additionally inserted a gene encoding serine palmitoyl-transferase and a gene encoding sphinganine C4-hydrosilase, comprising a CEN / ARS replication origin and / or uracil selection marker. As an example, the expression plasmid having a backbone of p416GPD, containing a CEN / ARS replication origin, and overexpressing LCB1 and LCB2, which are genes encoding serine palmitoyl-transferase, and SYR2, which is a gene encoding sphinganine C4-hydrosilase, may be pEXP, but is not limited thereto.
[0054] In another embodiment, the expression plasmid of the present invention may be an expression plasmid further comprising a homologous arm of a gene encoding a long-chain base kinase. For example, it may be pCM1842, a deletion plasmid that uses the pCM184 plasmid as a backbone, includes a uracil selection marker, and includes a homologous arm of LCB4, a gene encoding a long-chain base kinase, which can delete the LCB4 gene using the cre-loxP system, but is not limited thereto.
[0056] The vector of the present invention can direct the expression of a gene encoding a target protein linked for operability, and such a vector is called an expression vector. Generally, in the use of recombinant DNA technology, the expression vector is in the form of a plasmid.
[0057] The types of expression vectors available may be determined depending on the host cell. When Wicker hemomysis ciferae are used as the host, for example, pSH471, pSH472, pEXP, pCM1841, and pCM1842 vectors may be used as expression vectors, and ENO1 promoter, TDH3 promoter, and GPD promoter may be used as promoters, but are not limited thereto.
[0059] Methods for introducing DNA into Wicker hemomysis cyperal include, for example, the electroporation method (Method Enzymol., 194, 182-187 (1990)), the spheroplast method (Proc. Natl. Acad. Sci.USA, 84, 1929-1933 (1978)), and the lithium acetate method (J. Bacteriol., 153, 163-168 (1983)).
[0060] In addition, the above expression vector may additionally include an expression-inhibiting fragment having various functions for inhibiting, amplifying, or inducing the expression of a target gene, a marker for selecting a transformant, a resistance gene to an antibiotic, a gene encoding a signal intended for secretion outside the cell, a customized fusion factor suitable for a poorly expressed protein, etc.
[0061] In the present invention, the term "transformation" refers to the introduction of DNA into a host cell so that the DNA becomes replicable as an extrachromosomal factor or through the completion of chromosomal integration.
[0062] Any host cell widely known in the art can be used for the transformation according to the present invention, but a host cell with high introduction efficiency and expression efficiency of the genes encoding LCB1, 2, and SYR2 of the present invention can be used, and furthermore, the LCB4 gene can be deleted, and the present invention is characterized by using Wicker hemomysis cyperae.
[0064] Another embodiment of the present invention for achieving the above objective is a Wicker Hemomyces cyperai with enhanced tetraacetylphytosphingosine (TAPS) production capacity, which further enhances the activity of serine palmitoyl-transferase and sphinganine C4-hydrosylase and further weakens the activity of long-chain base kinases using an expression plasmid comprising the CEN / ARS replication origin and uracil selection marker. Wickerhamomyces ciferrii Provides a strain.
[0065] The terms of the present invention, “Wicker Haemomyces cyperai strain”, “CEN / ARS replication origin”, “uracil selection marker”, “expression plasmid”, “serine palmitoyl-transferase”, “sphinganine C4-hydrosilase”, and “long-chain base kinase” are as described above.
[0066] The term “Tetraacetylphytosphingosine (TAPS)” of the present invention refers to a compound having the structure of the following chemical formula I.
[0067]
[0069] It is known that in the microorganism of the present invention, TAPS is biosynthesized through a continuous process of biosynthesis shown in Fig. 1.
[0071] It has been confirmed that the strain of Wicker Haemomysis ciferae provided in the present invention is a novel mutant strain of Wicker Haemomysis ciferae with enhanced TAPS production ability through improved metabolic flow for synthesizing palmitoyl-CoA, and in the present invention, the strain of Wicker Haemomysis ciferae can be used in combination with the mutant strain of Wicker Haemomysis ciferae or the mutant strain.
[0072] In addition, the novel strain of Wicker hemomysis ciferae of the present invention may be the one deposited under accession number KCTC14970BP.
[0074] In the present invention, the terms “enhanced activity” or “weakening activity” each refer to enhancing or weakening the activity of a protein.
[0075] Methods for introducing, enhancing, or inactivating the activity of specific proteins and / or genes may be carried out using suitable methods known in the field, depending on the characteristics of the microorganism.
[0076] In this application, the term "enhancement" of protein activity means that the activity of said protein is introduced or increased relative to its intrinsic activity. The "introduction" of said activity means that the activity of a specific polypeptide, which the microorganism did not originally possess, becomes apparent naturally or artificially.
[0077] In this application, the term "increase" in protein activity relative to intrinsic activity means that the activity of a protein possessed by a microorganism is enhanced compared to its intrinsic activity or activity prior to modification. The "intrinsic activity" refers to the activity of a specific protein originally possessed by the parent strain or the non-modified microorganism prior to genetic change, in cases where the phenotype of the microorganism changes due to genetic mutation caused by natural or artificial factors. It may be used interchangeably with "activity prior to modification." The increase in activity may include both the introduction of an external protein and the enhancement of intrinsic protein activity. The increase / enhancement of protein activity may be achieved by increasing / enhancing gene expression.
[0078] Specifically, in this application, the increase in activity is,
[0079] 1) Increase in the copy number of the polynucleotide encoding the above protein,
[0080] 2) Modification of the expression-regulating sequence to increase the expression of the above polynucleotide,
[0081] 3) Modification of the polynucleotide sequence on the chromosome to enhance the activity of the above protein,
[0082] 4) Introduction of an exogenous polynucleotide exhibiting the activity of the above protein or a polynucleotide of a codon-optimized variant of the above polynucleotide, or
[0083] 5) This may be performed by methods such as modifying it to be reinforced by a combination of these, but is not limited thereto.
[0085] The increase in the copy number of the above 1) polynucleotide may be performed, but is not particularly limited thereto, by being operably linked to a vector or by being inserted into a chromosome within a host cell. Specifically, it may be performed by introducing a polynucleotide encoding the protein of the present invention into a host cell by operably linking it to a vector capable of replicating and functioning independently of the host, or by increasing the copy number of the polynucleotide within the chromosome of the host cell by introducing the polynucleotide into the host cell by operably linking it to a vector capable of inserting the polynucleotide into a chromosome within the host cell.
[0086] Next, 2) modification of the expression-regulating sequence to increase the expression of the polynucleotide may be performed, but is not specifically limited thereto, by inducing a sequence variation in the nucleic acid sequence through deletion, insertion, non-conservative or conservative substitution, or a combination thereof, to further enhance the activity of the expression-regulating sequence, or by replacing it with a nucleic acid sequence having stronger activity. The expression-regulating sequence may include, but is not specifically limited thereto, a promoter, an operator sequence, a sequence encoding a ribosome binding site, a sequence regulating the termination of transcription and translation, etc.
[0087] A strong heterologous promoter may be connected to the upper portion of the above polynucleotide expression unit instead of the original promoter, but is not limited thereto. In addition, 3) modification of the polynucleotide sequence on the chromosome may be performed, but is not particularly limited thereto, by inducing a variation in the expression-regulating sequence through deletion, insertion, non-conservative or conservative substitution, or a combination thereof, to further enhance the activity of the above polynucleotide sequence, or by replacing it with a polynucleotide sequence improved to have stronger activity.
[0088] In addition, 4) the introduction of an exogenous polynucleotide sequence may be performed by introducing into a host cell an exogenous polynucleotide encoding a protein that exhibits activity identical or similar to that of the protein, or a polynucleotide with a codon optimized variant thereof. The exogenous polynucleotide may be used without restriction on its origin or sequence as long as it exhibits activity identical or similar to that of the protein. Furthermore, the exogenous polynucleotide may be introduced into a host cell by optimizing its codons so that optimized transcription and translation occur within the host cell. The introduction may be performed by a person skilled in the art by appropriately selecting a known transformation method, and the protein may be produced and its activity increased as the exogenous polynucleotide is expressed within the host cell.
[0090] Finally, 5) a method of modification to be enhanced by a combination of 1) to 4) above may be performed by applying one or more of the following methods together: increasing the copy number of the polynucleotide encoding the protein, modifying the expression-regulating sequence to increase its expression, modifying the polynucleotide sequence on the chromosome, and modifying an exogenous polynucleotide or a codon-optimized variant of the polynucleotide that exhibits the activity of the protein.
[0092] In a specific embodiment of the present invention, an effective expression plasmid capable of operating in Wicker Haemomyces cyperai was constructed, and using this specific expression plasmid, the activity of protein serine palmitoyl transferase and sphinganine C-4-hydroxylase was enhanced simply and effectively by introducing the LCB1, 2, and SYR2 genes, and furthermore, by deleting the LCB4 gene to weaken the long-chain base kinase activity, it was confirmed that the TAPS production capacity of the prepared Wicker Haemomyces cyperai strain was significantly increased.
[0094] Another embodiment of the present invention for achieving the above objective provides a strain of Wicker Haemomysis ciferae with enhanced tetraacetylphytosphingosine (TAPS) production capacity, wherein the activity of serine palmitoyl-transferase and sphinganine C4-hydroxylase is enhanced and the long-chain base kinase activity is further weakened using an expression plasmid containing a CEN / ARS replication origin in a uracil-selective nutrient-requiring Wicker Haemomysis ciferae strain containing a uracil selector marker.
[0095] The terms of the present invention, “Wicker Haemomyces cyperai strain,” “CEN / ARS replication origin,” “uracil selection marker,” “expression plasmid,” “serine palmitoyl-transferase,” “sphinganine C4-hydroxylase,” “long-chain base kinase,” and “tetraacetylphytosphingosine (TAPS)” are as described above.
[0097] Another embodiment of the present invention provides a composition for producing tetraacetylphytosphingosine (TAPS), comprising the strain, a culture of the strain, a lysate of the strain, or an extract of the strain.
[0098] The terms of the present invention, “Wicker Haemomyces cyperai strain” and “tetraacetylphytosphingosine (TAPS)”, are as described above.
[0099] In the present invention, the term “culture of a strain” refers to a culture of the strain Wicker hemomycis ciferae of the present invention, and refers to a culture product produced by culturing the strain of the present invention in a culture medium. For example, it may include a filtrate of the culture of the strain of the present invention or a culture supernatant obtained by centrifuging the culture.
[0100] The term “crushed material” means a crushed material of the Wicker Haemomyces cyperii strain of the present invention, comprising all useful substances present within the strain that can be released by crushing the strain.
[0101] The term “extract thereof” refers to an extract obtained by extracting the strain of Wicker hemomysis ciferae of the present invention using a solvent, wherein the solvent may be included without limitation as long as it is known, and the extraction method may also be included without limitation.
[0102] The term “extract of culture” refers to an extract obtained by extracting the culture of the strain of Wicker hemomysis ciferae of the present invention using a solvent, wherein the solvent may be included without limitation as long as it is known, and the extraction method may also be included without limitation.
[0103] The term “extract of lysed material” refers to an extract obtained by extracting the lysed material of the Wicker hemomycis ciferae strain of the present invention using a solvent, wherein the solvent may be included without limitation as long as it is known, and the extraction method may also be included without limitation.
[0104] The strain of Wicker Haemomyces siferae of the present invention, its culture, its lysate, its extract, the extract of the culture, or the extract of the lysate may be included in an amount of 10 to 50 weight% relative to the composition, but is not limited thereto. Specifically, if the amount is less than 10 weight%, the effect is negligible, and if the amount exceeds 50 weight%, the increase in effect relative to the amount used is insignificant, which may be uneconomical.
[0106] Another embodiment of the present invention provides a method for producing tetraacetylphytosphingosine using the above-mentioned Wicker Hemomyces cyperai mutant strain.
[0107] Specifically, the method for producing tetraacetylphytosphingosine of the present invention comprises the step of culturing the above-mentioned mutant strain of Momais cyperai to obtain a culture, and may additionally include the step of recovering tetraacetylphytosphingosine from the obtained culture.
[0108] At this time, the description of the above “Wicker Hemomyces cyperai” and “tetraacetylphytosphingosine” is as described above.
[0109] The term “culture” above refers to enabling the recombinant microalgae to grow, and the culture medium and culture conditions for culturing the transformant of the present invention may be appropriately selected and used depending on the host cell. It is preferable that the nutrient medium contains a carbon source, an inorganic nitrogen source, or an organic nitrogen source necessary for the growth of the host cell. Examples of carbon sources include glucose, dextran, soluble starch, sucrose, and methanol. Examples of inorganic nitrogen sources or organic nitrogen sources include ammonium salts, nitrates, amino acids, corn steep liquer, peptone, casein, bovine extract, soybean bag, and potato extract. If necessary, other nutrients may be included, for example, inorganic salts such as sodium chloride, calcium chloride, sodium dihydrogen phosphate, and magnesium chloride, vitamins, and antibiotics (tetracycline, neomacin, ampicillin, and kanamycin). During culture, conditions such as temperature, pH of the medium, and culture time can be appropriately controlled to be suitable for cell growth and mass production of protein.
[0111] In the above method, the step of culturing the microorganism is not particularly limited thereto, but can be performed by known batch culture methods, continuous culture methods, fed-batch culture methods, etc., and as an example, it can be cultured by a fed-batch culture method.
[0112] At this time, the culture conditions may be adjusted to an appropriate pH (e.g., pH 5 to 9, specifically pH 6 to 8, most specifically pH 6.8) using a basic compound (e.g., sodium hydroxide, potassium hydroxide, or ammonia) or an acidic compound (e.g., phosphoric acid or sulfuric acid), although not specifically limited thereto, and may maintain aerobic conditions by introducing oxygen or an oxygen-containing gas mixture into the culture medium. The culture temperature may be maintained at 20 to 45°C, specifically 25 to 40°C, and may be cultured for about 10 to 200 hours, but is not limited thereto. Putrescine produced by the above culture may be secreted into the medium or remain in the cell.
[0113] In addition, the culture medium used may contain serine, glutamate, glycine, or a combination thereof, and specifically may contain a combination of glutamate and glycine.
[0114] In a specific embodiment of the present invention, it was confirmed that when the novel strain of Wicker hemomyces siferae of the present invention is cultured in a fed-batch manner, the addition of a combination of glutamate and glycine to the medium effectively produces TAPS and yields a higher yield compared to when other amino acids or a single amino acid are added.
[0116] The above culture medium may additionally include a carbon source, a nitrogen source, and / or a phosphorus source, and may additionally include other sources.
[0117] As carbon sources, sugars and carbohydrates (e.g., glucose, sucrose, lactose, fructose, maltose, molasses, starch, and cellulose), oils and fats (e.g., soybean oil, sunflower oil, peanut oil, and coconut oil), fatty acids (e.g., palmitic acid, stearic acid, and linoleic acid), alcohols (e.g., glycerol and ethanol), and organic acids (e.g., acetic acid) may be used individually or in combination, but are not limited thereto. As nitrogen sources, nitrogen-containing organic compounds (e.g., peptone, yeast extract, meat juice, malt extract, corn steep liquid, soybean meal, and urea), or inorganic compounds (e.g., ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate, and ammonium nitrate) may be used individually or in combination, but are not limited thereto.
[0118] Potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and equivalent sodium-containing salts may be used individually or in combination as phosphorus sources, but are not limited thereto, and may be KH2PO4 as an example.
[0119] In addition, the culture medium may contain other metal salts (e.g., magnesium sulfate or iron sulfate), essential growth-promoting substances such as amino acids and vitamins.
[0120] In addition, the culture medium may additionally contain an antifoaming agent.
[0121] In the present invention, the term “defoamer” refers to a substance that removes harmful bubbles, and generally, an oily substance with low volatility and high diffusivity, or a water-soluble surfactant, may be used.
[0123] The method for recovering TAPS produced in the above-mentioned culture step of the present invention may collect the desired amino acid from the culture medium using a suitable method known in the art according to the culture method. For example, centrifugation, filtration, anion exchange chromatography, crystallization, and HPLC may be used, and the desired TAPS may be recovered from the culture medium or microorganisms using a suitable method known in the art.
[0125] Another embodiment of the present invention provides a method for producing a strain of Wicker Haemomyces cyferae with enhanced tetraacetylphytosphingosine (TAPS) production capacity. Specifically, the method may include the steps of: producing a uracil-requiring Wicker Haemomyces cyferae strain; enhancing the activity of serine palmitoyl-transferase and sphinganine C4-hydroxylase with an expression plasmid containing a CEN / ARS replication origin; and weakening the activity of long-chain base kinases.
[0126] At this time, the descriptions of the above “Wicker Hemomyces cyperai,” “tetraacetylphytosphingosine,” “CEN / ARS replication origin,” “expression plasmid,” “serine palmitoyl-transferase,” “sphinganine C4-hydroxylase,” “enhanced activity,” “long-chain base kinase,” and “increased activity” are as described above.
[0128] In a specific embodiment of the present invention, in order to construct an effective expression plasmid capable of operating in Wicker Haemomyces schiferae and to express genes simply and effectively, various origin tests used in conventional yeast were performed to locate the CEN / ARS origin, and a uracil-requiring Wicker Haemomyces schiferae strain was constructed using 5-FOA to secure an efficient selection marker. Then, after cloning the gene to be overexpressed into the expression plasmid containing the CEN / ARS origin and the uracil selection marker, the gene was transformed into the constructed uracil-requiring Wicker Haemomyces schiferae strain, and strain YP1, which had the best TAPS production, was selected. It was confirmed that the final titer of YP1 was 2.68 g / L, which is 1.8 times higher than the titer of the uracil-requiring strain, which is 1.46 g / L. In addition, it was confirmed that the TAPS titer of YPD7 obtained through LCB4 gene deletion was 3.03 g / L, which is twofold higher than that of the control group. Finally, by optimizing the medium conditions by adding an amino acid, a precursor related to serine synthesis, to the medium, it was confirmed that the final strain YPD7 could produce TAPS at a very high concentration of 20 g / L, which is higher than previously known.
[0129] This suggests that TAPS production in fed-batch culture can be improved more effectively when engineering using a uracil-nutrient-requiring Wicker Haemomysis cyperai mutant strain constructed with an expression plasmid having a specific replication origin and uracil selection marker. Effects of the invention
[0131] The Wicker Hemomyces cyperai variant provided in the present invention has excellent productivity of TAPS, so it can be widely utilized in the development of various products using TAPS. Brief explanation of the drawing
[0133] Figure 1 is a diagram showing the biosynthetic pathway of TAPS. Figure 2 is a schematic diagram of the present invention. Figure 3 is a diagram showing the manufacturing process of uracil-dependent Wicker hemomycis cyperais. Figure 4 is a figure showing the Ends-in and Ends-out methods of the cre-loxP system. Figure 5 shows four types of plasmids used in yeast. Figure 6 is a figure showing the CEN / ARS origin with KanMX and URA3 selection markers. Figure 7 shows EGFP expression using a CEN / ARS-derived expression plasmid. Figure 8 is a figure showing TAPS production according to amino acid supplementation. Figure 9 shows a candidate Y94 strain with the expression plasmid pEXP. Figure 10 shows the TAPS titer and yield of the YP1 strain and the YP11 strain. Figure 11 shows the TAPS potency and yield of the YD94 strain and the YPD7 strain. Figure 12 shows high cell density fermentation using the final strain YPD7. Specific details for implementing the invention
[0134] The present invention will be explained in more detail below through examples. These examples are intended to explain the invention more specifically, and the scope of the invention is not limited by these examples.
[0136] Experimental Example 1: Construction of Strains and Plasmids
[0137] Wickerhamomais Ciferai Wickerhamomyces ciferrii Considering that expression plasmids are not yet applicable to ), we intended to construct an expression plasmid that can work in Wicker Hemomyces cyperai to secure a simpler and more effective gene overexpression method.
[0138] First, a uracil-dependent strain was constructed by optimizing the replication origin and selection markers in the expression plasmid. Then, TAPS production was increased by overexpressing LCB1 and LCB2 encoding SPT and SYR2 encoding sphinganine C4-hydroxylase. Additionally, TAPS production was improved by deleting LCB4. Finally, high cell density fermentation was performed to achieve high TAPS production (Fig. 2).
[0140] All engineered strains, recombinant plasmids, and oligomers used in the present invention are as shown in Tables 1 and 2 below.
[0141] Name Description Reference Strains WT Y94 W. ciferrii uracil auxotroph This study YP1 Y94 with pEXP, colony No.1 This study YD94-M Y94 △ LCB4 with selection marker This study YD94 Y94 △ LCB4 without selection marker This study YPD7 Y94 △ LCB4 with pEXP, colony No.7 This study Plasmids pSH47 AmpR , ColE1 origin, GAL1 promoter, Cre recombinase :: URA3 , CEN / ARS origin Addgene pSH471 pSH47:: egfp This study pSH471_ARS pSH471:: URA3 , ARS origin △CEN / ARS This study pSH471_2μ pSH471:: URA3 , 2μ origin △CEN / ARS This study pSH472 pSH471:: KanMX △ URA3 , This study pSH472_ARS pSH472:: KanMX, ARS origin △CEN / ARS This study pSH472_2μ pSH472:: KanMX , 2μ origin △CEN / ARS This study p416GPD AmpR , CEN / ARS origin, pBR322 origin, GPD promoter, URA3 ATCC (Manassas, USA) pEXP p416GPD harboring P ENO1 ::LCB1 , P TDH3 :: LCB2 , P GPD ::SYR2 This study pCM184 AmpR , KanR , ColE1 origin, loxP Addgene pCM1841 pCM184:: URA3 This study pCM1842 pCM1841::homology arms of LCB4 from W. ciferrii This study
[0143]
[0144]
[0146] Wicker Hemomyces siferae ATCC 14091 was used as the parent strain to construct a uracil-requiring strain named Y94, obtained by 5-FOA (Fluoroorotic acid) random mutagenesis. To construct the uracil-requiring strain Y94, 0.1 g / L 5-FOA was added to YEPD medium, and the wild-type (WT) strain was inoculated. As the strain grew, the concentration of 5-FOA in the medium was gradually increased to obtain a strain growing in a medium containing 1.5 g / L 5-FOA. The obtained strain was screened on YEPD agar plates containing 1.5 g / L 5-FOA. Then, 40 colonies were selected from a master plate containing SD plates with uracil and plates without uracil. Additionally, luminescent colonies were selected from plates without uracil. These photogrowth colonies were screened again in a medium containing 5-FOA in the same manner as above to select photogrowth colonies. Through this process, strains were obtained that grow on SD plates containing uracil but not on plates without uracil. Finally, it was confirmed that the strains obtained in this way do not grow in liquid media without uracil (Fig. 3).
[0148] one side, E. coliDH5α was used as a host for gene cloning. To construct pSH471, egfp was introduced into the pSH47 plasmid using the primer set of egfp_for and egfp_rev. Subsequently, the PCR products of egfp and pSH47 were cleaved using HindIII and EcoRI and ligated using NEBuilder HiFi DNA Assembly Master Mix (New England Biolabs, MA, USA). Origin testing was performed using plasmid pSH471 containing the URA3 selection marker and pSH472 containing the KanMX marker. To construct the pSH472 plasmid, the primer set of KanMX_for and KanMX_rev was used from the pML104 plasmid and ligated using NEBuilder HiFi DNA Assembly Master Mix. Subsequently, the CEN / ARS origin for each plasmid was changed to the ARS origin and 2μ origin using the primer sets of ARS_for and ARS_rev and 2μ_rev, respectively. ARS was amplified from the S. cerevisiae genome sequence, and the 2μ origin was amplified in the pML104 plasmid. To prepare pEXP, the p416GPD plasmid was used as the backbone. For the overexpression of LCB1, LCB2, and SYR2, the ENO1 promoter, TDH3 promoter, and GPD promoter were used, respectively. First, the PCR products were amplified using the primer sets of ENO1_for and ENO1_rev / LCB1_for, LCB1_rev / TDH3_for, TDH3_rev / LCB2_for, LCB2_rev / SYR2_for, and SYR2_rev (Table 2).
[0149] Then, the amplified DNA fragment was inserted into the p416GPD plasmid, which had been cleaved by EagI using NEBuilder HiFi DNA Assembly Master Mix. To construct the LCB4 deletion vector, the pCM184 plasmid was used as the backbone. To perform gene deletion in the Y94 strain, pCM1841 was constructed by introducing the URA3 selection marker into pCM184. For the construction of pCM1841, URA3 was amplified using the primer set EO_for and EO_rev, and pCM184 was cleaved using PstI. Then, the two fragments were ligated using NEBuilder HiFi DNA Assembly Master Mix. After constructing pCM1841, the left homology region (LHR) of LCB4 was amplified using the primer set LCB4_LHR_for and LCB4_LHR_rev. For pCM1841 and the LHR fragment, they were cleaved with EcoRI and KpnI and ligated with Mighty Mix (Takara, Shiga, Japan). Then, the right homologous region (RHR) of LCB4 was inserted into pCM1841 containing the LHR of LCB4. The vector was cleaved with SacI and ligated with the PCR products of the amplified RHR using LCB4_RHR_for and LCB4_RHR_rev with NEBuilder HiFi DNA Assembly Master Mix. These PCR products were amplified using Q5 High-Fidelity DNA Polymerase (New England Biolabs, MA, USA) via a T100 Thermal Cycler (Bio-rad, CA, USA).
[0150] Here, all restriction enzymes were purchased from New England Biolabs. Additionally, all vectors were transformed using an Eporator (Eppendorf, Hamburg, Germany) with a voltage of 2500 V. After transforming pEXP into Y94, W. ciferrii YP1 and YP11 were obtained. After transformation with pEXP, 12 colonies were pre-cultured with control strains WT and Y94. Then, YP1 and YP11, which showed higher TAPS titers compared to WT and Y94, were selected. The LCB4 gene was deleted by the cre-loxP system using the Ends-out method with homologous cancer pCM1842 to produce YD94 (Fig. 4). Then, pEXP was transformed into YD94. Similarly, 12 colonies were pre-cultured to obtain YPD7, which showed improved TAPS production.
[0152] Experimental Example 2. Medium and Culture
[0153] E. coli DH5α for gene cloning was cultured at 37°C in Luria-Bertani (LB) broth (5 g / L yeast extract, 10 g / L tryptone, and 10 g / L NaCl). 50 μg / L carbenicillin was supplemented for selection. Wild-type seed strains of *Wicker Haemomyces schiferae* were grown in 3 ml YEPD medium (10 g / L Bacto yeast extract, 20 g / L Bacto peptone, and 100 ml / L 20% D-glucose). Uracil-dependent strains were grown in SD medium (6.7 g / L YNB w / o amino acids, and 100 ml / L 20% D-glucose) containing a selected amino acid mixture (10 ml / L L-histidine, L-leucine, L-tryptophan). Then, the seed strain was inoculated into 5 ml of TAPS medium (100 g / L glycerol, 2 g / L yeast extract, 3 g / L KNO3, 3 g / L sodium acetate, 1 g / L NH4NO3, and 1.5 g / L corn steep powder) and cultured for 1.5 days. After pre-culture in TAPS medium, it was re-inoculated into 50 ml of fresh TAPS medium with an OD600 of 0.1 for main culture. The entire culture procedure was performed aerobically at 30 °C in a shaking incubator at 250 rpm.
[0154] Feed-batch fermentation of Wicker Hemomyces cyperai YPD7 was carried out for 7 days in a 3L bioreactor using 1L of TAPS medium containing 100g / L glycerol, 1g / L KH2PO4, and 1g / L MgSO4. At this time, the initial OD600 of fermentation was 1.0. Feed-batch fermentation was performed at 30°C with an aeration rate of 1L / min and a stirring rate of 650 rpm. The aeration and stirring rates were increased to 5L / min and 800 rpm, respectively, to maintain dissolved oxygen above 30%. For additional supply, 1000g / L of glycerol feedstock was added to check the residual glycerol concentration, after which the glycerol concentration was maintained at 100g / L. In addition, 10 ml of 100 g / L amino acids (glutamate and glycine), 10 ml of 200 g / L yeast extract, 10 ml of 100 g / L MgSO4, and 10 ml of 100 g / L KH2PO4 feedstock were added every 24 hours.
[0156] Experimental Example 3. Analysis Method
[0157] The growth of the strain was confirmed by measuring the optical density (OD600) using a DU730 UV-Vis spectrophotometer (Beckman coulter, Brea, CA, USA). EGFP expression was measured using a Biotek Synergy H1 microplate reader (Biotek, VT, US). Glycerol concentration in the medium was measured after centrifugation of the culture using high-performance liquid chromatography (HPLC) equipped with a Waters 2414 refractive index detector (Waters, Milford, MA, USA) and a Shodex SH1011 column (Shodex, Tokyo, Japan), with 10 mM H2SO4 as the mobile phase at a flow rate of 0.6 mL / min.
[0158] Next, TAPS production was measured using 250 μL of each liquid culture sample for TAPS analysis. Specifically, the sample was mixed with 1 ml of acetone and vortexed for 30 minutes. Then, 700 μL of the supernatant was collected by centrifugation, and the collected supernatant was analyzed using an HPLC equipped with a Waters 2695 HPLC (Waters, Milford, MA), an Agilent XDB-C18 column (Agilent, Santa Clara, CA), and a Waters 2487 detector (Waters, Milford, MA). A mobile phase consisting of methanol (81.5% w / w), H2O (18.45% w / w), and trifluoroacetic acid (0.05% w / w) was used at a flow rate of 1.4 ml / min for 30 minutes / run. Here, the wavelength for UV detection was 200 nm.
[0160] Example 1. Establishment of expression plasmid of Wicker hemomyces cyperai
[0161] There are four types of plasmids used in yeast: yeast cloning plasmid of ARS origin (YRp), yeast centrosome plasmid of CEN / ARS origin (YCp), yeast episome plasmid of 2μ origin (YEp), and yeast integration plasmid (YIp), the yeast integration plasmid has no origin and can be directly integrated into the host chromosome through homologous recombination (Fig. 5).
[0162] Accordingly, we first determined which origin could function in Wicker Haemomysis ciferae. Specifically, three plasmids containing ARS, CEN / ARS, and 2μ origins were each transformed into Wicker Haemomysis ciferae WT. These plasmids were derived from pSH47 containing the KanMX selection marker. Since Colony PCR is not applicable to Wicker Haemomysis ciferae, gDNA was extracted to confirm whether the plasmids were present. Forward and reverse primers were set to the lateral position sequences of the origins, and PCR was performed to confirm whether Wicker Haemomysis ciferae possessed the plasmids. As a result, as can be seen in Fig. 6A, it was confirmed that the ARS origin plasmid and the 2μ origin plasmid were not present in Wicker Haemomysis ciferae, but only the CEN / ARS origin plasmid was retained (Fig. 6A).
[0163] Next, the green fluorescent protein egfp was expressed and the fluorescence level was measured to confirm whether the gene within the plasmid was being stably expressed within the strain. As a result, as can be seen in Figure 7, it was confirmed that egfp was being stably expressed within the strain (Figure 7).
[0165] Meanwhile, the KanMX selection marker, which is resistant to Kanamycin / G418, is an antibiotic marker used in yeast. However, the aforementioned selection marker has several disadvantages, such as low selection efficiency and instability. Therefore, there is a need to construct a new and efficient selection marker. Generally, 5-Fluoroorotic acid (5-FOA) is used in yeast genetics to confirm the absence of the URA3 gene. This is because URA3 leads to death, including the decarboxylation reaction from 5-FOA to the toxic metabolite 5-fluorouracil (Boeke et al., 1987; Luo et al., 2021; Shivhare et al., 2021). Using this 5-FOA, a uracil-dependent strain was successfully produced through the screening process of Experimental Example 1. Subsequently, the origin test was performed again using the newly produced uracil-dependent strain. As a result of cloning three origins into a plasmid containing the URA3 selection marker, it was reconfirmed that only the CEN / ARS-derived plasmid was maintained within the strain, as can be seen in Fig. 6B and consistent with the results previously confirmed in Fig. 6A. Furthermore, unlike the case where kanamycin was the selection marker, bands appeared in all colonies, demonstrating a transformation efficiency of 100%. Through this, it was confirmed that a strain with an efficient and stable selection marker was effectively established (Fig. 6B).
[0167] Example 2. Genetic engineering for TAPS production
[0168] Using the strain prepared in Example 1 above, an experiment was conducted to investigate the effect of adding certain amino acids on TAPS production. First, since serine is a precursor of TAPS and glutamate and glycine are most effective for TAPS production, wild-type culture was performed by adding three amino acids to the TAPS medium (Fig. 8). The amino acids were added to the medium when the cells entered the early-mid exponential phase (24 hours). As a result of these amino acid tests, as can be seen in Fig. 8, it was confirmed that the TAPS titer was highest in the stationary phase when glutamate and glycine were added together to the medium. In particular, the TAPS titer of the WT strain was 1.65 g / L only in the TAPS medium, whereas it was confirmed to be 2.5 g / L, which is a 1.5-fold increase, in the TAPS medium containing glutamate and glycine. The yield was also highest at 0.032 gTAPS / gglycerol in the medium containing glutamate and glycine, and it was confirmed that the WT was 0.022 gTAPS / gglycerol.
[0170] Subsequently, after optimizing the medium conditions, Wicker Haemomysis ciferae were engineered to overexpress LCB1, LCB2, and SYR2 using an expression plasmid containing the CEN / ARS origin and URA3 selection marker. Here, LCB1 and LCB2 are genes encoding SPT, and SYR2 is a gene encoding sphinganine C4-hydroxylase. Overexpression of these genes through promoter engineering in the genome has been reported to increase TAPS production by 57% in conventional S. cerevisiae (Schorsch et al., 2012). To overexpress these genes with p416GPD, three potent promoters available in Wicker Haemomysis ciferae were selected. The LCB1 and LCB2 genes were overexpressed at the ENO1 and TDH3 promoters, respectively, and SYR2 was overexpressed at the GAP promoter. A pEXP expression plasmid having the three genes and three potent different promoters was transformed into the Y94 strain. After transformation, 12 colony candidates were selected for pre-culture in aerobic tubes. After 4 days of culture, two candidates, YP1 and YP11, which showed better TAPS production than the wild type, were selected (Fig. 9). Culture of YP1 and YP11 was performed in TAPS medium supplemented with glutamate and glycine compared to the control strain (Fig. 10).
[0171] As a result, as can be seen in Fig. 11, the TAPS titers of each WT strain and Y94 strain were 2.3 g / L and 1.46 g / L, respectively, whereas the TAPS titers of YP1 and YP11 were 2.68 g / L and 1.9 g / L, respectively. The titer of YP1 was higher than that of the wild type and Y94. The yield also increased by 0.036 g TAPS / g glycerol, which was confirmed to be 1.8 times higher than that of Y94 (Fig. 11).
[0173] Furthermore, to increase TAPS production, YD94 was produced by deleting LCB4, which encodes a long-chain base kinase, into the cre-loxP system.
[0174] There are two methods for replacing target genes based on homologous recombination: Ends-in and Ends-out. Since the Ends-out method is primarily used, a deletion system was constructed using the Ends-out method. To establish the deletion method, the pCM184 plasmid was used in homologous cancers for the target gene and loxP region containing the URA3 selection marker, and the pSH47 plasmid was used in Cre recombinase containing the KanMX selection marker. As a result, the TAPS titer of YD94 was 2.25 g / L and the yield was 0.0252 gTAPS / gglycerol, confirming that TAPS production was higher than that of the parent strain Y94 (Fig. 11). YPD7 was produced by transforming this YD94 with pEXP. Subsequently, YPD7 was cultured, and the TAPS titer and yield were measured (Fig. 11). As a result, the TAPS potency and the yield of YPD7 were 3.03 g / L and 0.03675 gTAPS / gglycerol, respectively, which were confirmed to be twofold higher than those of the parent strain Y94. For reference, the YPD7 strain produced here was deposited with the Korea Research Institute of Biotechnology and Bioengineering on May 4, 2022, under accession number KCTC14970BP.
[0176] In conclusion, it can be confirmed that overexpression using an expression plasmid containing the CEN / ARS origin and URA3 selection marker in Wicker Hemomyces cyperai and deletion using the cre-loxP system effectively enable improvement in TAPS production.
[0178] Example 3. Fed-batch culture for TAPS production
[0179] To achieve high production in TAPS, high cell density fermentation was performed using YPD7 as the final strain. The culture method was fed-batch, and glycerol, glutamate, and glycine were periodically added to the culture medium. In addition, to promote growth, nutrients such as MgSO4, which improves lipid productivity, and KH2PO4, a source of phosphorus (P), were supplemented. To prevent foaming, an antifoaming agent was connected to the fermenter and supplied automatically.
[0180] As a result, as can be seen in Fig. 12, the highest TAPS potency was 20.2 g / L and the productivity was 0.12 g / L / h (Fig. 12).
[0181] Through this, it was confirmed that fed-batch fermentation with periodic supply of glycerol, glutamate, glycine, MgSO4, and KH2PO4 achieved the highest TAPS activity compared to previous studies (Table 3).
[0183]
[0185] In summary, to construct an effective expression plasmid capable of functioning in Wicker Haemomysis ciferae and to express genes simply and effectively, various origin tests used in conventional yeast were performed to locate the CEN / ARS origin, and a uracil-requiring Wicker Haemomysis ciferae strain was constructed using 5-FOA to secure an efficient selection marker. Next, the gene to be overexpressed was cloned into the expression plasmid containing the CEN / ARS origin and the uracil selection marker, and then transformed into the aforementioned uracil-requiring Wicker Haemomysis ciferae strain. The strain YP1, which had the best TAPS production, was selected, and it was found that the final titer of YP1 was 2.68 g / L, which is 1.8 times higher than the titer of the uracil-requiring strain, 1.46 g / L. In addition, it was confirmed that the TAPS potency of YPD7 obtained through LCB4 gene deletion was 3.03 g / L, which is twofold higher than that of the control group. Furthermore, by optimizing the medium conditions by adding amino acids, which are precursors related to serine synthesis, to the medium, it was confirmed that the final strain YPD7 could produce TAPS at a very high concentration of 20 g / L, which is higher than previously known.
[0186] This suggests that TAPS production in fed-batch culture can be improved more effectively when engineering using a uracil-nutrient-requiring Wicker Haemomysis cyperai mutant strain constructed with an expression plasmid having a specific replication origin and uracil selection marker.
[0188] From the foregoing description, those skilled in the art to which the present invention pertains will understand that the present invention may be implemented in other specific forms without altering its technical concept or essential features. In this regard, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as including all modifications or variations derived from the meaning and scope of the claims set forth below and their equivalents, rather than from the detailed description above.
[0190] Depository: Korea Research Institute of Bioscience and Biotechnology Trustee Number: KCTC14970BP Date of Deposit: 2022-05-04
Claims
Claim 1 delete Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 delete Claim 7 delete Claim 8 delete Claim 9 delete Claim 10 delete Claim 11 delete Claim 12 A method for producing tetraacetylphytosphingosine (TAPS), comprising the step of culturing a strain of Wicker hemomyces schiferae deposited under accession number KCTC14970BP in a medium containing glutamate and glycine; wherein, in a uracil-nutritive Wicker hemomyces schiferae strain containing a uracil selection marker, the activity of serine palmitoyl-transferase and sphinganine C4-hydroxylase is enhanced using an expression plasmid containing a CEN / ARS replication origin, and the activity of long-chain base kinase, a protein that converts sphinganine to sphinganine-1-P, is further weakened, thereby enhancing the tetraacetylphytosphingosine (TAPS) production capacity. Claim 13 A method for producing tetraacetylphytosphingosine (TAPS) according to claim 12, wherein the serine palmitoyl-transferase is encoded as LCB1 or LCB2. Claim 14 A method for producing tetraacetylphytosphingosine (TAPS) according to claim 12, wherein the sphinganine C4-hydrosilase is encoded as SYR2. Claim 15 A method for producing tetraacetylphytosphingosine (TAPS) according to claim 12, wherein the long-chain base kinase is encoded by LCB4. Claim 16 delete Claim 17 delete Claim 18 delete Claim 19 delete
Citation Information
Patent Citations
A mutated strain over-producing tetraacetylphytosphingosine and process for preparing tetraacetylphytosphingosine using the same
KR102187234B1
Pichia ciferrii mutant strains Having Enhanced Spingoid Base and Sphingolipid Production And Preparation Method of the same
KR102343479B1
Method for producing phytosphingosine or sphinganine
US20180179562A1
Method for producing sphingoid base or sphingolipid
US20180179563A1
